Abstract: Among patients who interrupted 3TC, overall prevalence of M184V/I was 23.1%: proportion of patients carrying the M184V/I dropped from 83.3% among those who interrupted 3TC from < or = 3 months, to 56.3, 20, 10.5 and 0% for those interrupting 3TC from 6, 12, 24 and > or = 24 months, respectively.
Abstract: At logistic regression analysis, the rate of increase of M184V/I in 3TC-failing patients was statistically significant (OR: 1.066 per month of current 3TC therapy, 95% CI: 1.020-1.114, P<0.01), suggesting a 6.6% monthly increase of probability of M184V/I.
Abstract: At logistic regression, the rate of disappearance of M184V/I was also statistically significant (OR: 0.883 per month, 95% CI: 0.804-0.970, P=0.01), indicating a 11.7% monthly decrease of probability of
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
PMID: 12898440
2003
The Journal of infectious diseases
Abstract: In addition, most patients for whom the ddI-containing regimen failed lost the M184V/I mutation.
Abstract: These results show that ddI continues to provide activity against viruses with the M184V/I mutation and suggest that the presence of the M184V/I mutation should not preclude the use of ddI in nucleoside-experienced patients.
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
PMID: 14513419
2003
The Journal of infectious diseases
Abstract: The modulating effect of M184I/V on drug susceptibility was present regardless of the number of TAMs.
Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.
PMID: 14522102
2003
International journal of antimicrobial agents
Abstract: Mutations (M184V or M184I) conferring resistance to lamivudine were detected in an extremely high percentage of patients (61%).
Inhibition of human immunodeficiency virus reverse transcriptase by synadenol triphosphate and its E-isomer.
PMID: 14561099
2003
Journal of medicinal chemistry
Abstract: The extent of inhibition of two mutant forms of reverse transcriptase (RT), RT(M184V) and RT(M184I), with triphosphate 1c was about 5 and 8 times lower than that of wild-type RT(wt).
Drug resistance mutations during structured treatment interruptions.
Abstract: Among the 74 patients receiving lamivudine, the M184V/I mutation was detected in 13/74 (17.6%) patients.
Abstract: CONCLUSIONS: The M184V/I mutation is frequently selected during repeated treatment interruptions.
Abstract: The relative risk for virological failure was 2.55-fold higher in patients with the M184V/I mutation than in patients without detectable mutation (P=0.007).
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Abstract: Four of these five patients had either the K65R mutation, the M184V/I mutation, or both.
Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.
PMID: 11923351
2002
Journal of clinical microbiology
Abstract: Mutations conferring resistance to didanosine and lamivudine were detected in 2 (L74V and M184I; 14.2%) of 11 patients tested and in 4 (M184V; 57%) of 7 patients tested, respectively.
Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
PMID: 12118466
2002
The Southeast Asian journal of tropical medicine and public health
Abstract: The mutations associated with lamivudine resistance (M184V/I) were found most often (in 45.7% of individuals).
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
Abstract: Mutations within immunogenic regions of clade C RT were noted during drug selection of subtype C isolates with nevirapine (S98I, Y181C, V108I and K103N), delavirdine, (A62V, V75E, L100I, K103T, V108I, Y181C), efavirenz (K103E, V106M, V179D, Y188C/H, G190A), lamivudine (M184I, M184V), and zidovudine (K70R), respectively.
HIV mutation literature information.
PMID: 
2003
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT